N. L. Barlett

Articles by N. L. Barlett

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Leo I. Gordon, MD,G. A. Wiseman,S. Spies,C. Emmanouilides,Myron S. Czuczman, MD,I. W. Flinn,N. L. Barlett,J. L. Murray,B. Alkuzweny,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD,Christine A. White, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with

Latest Updated Articles

$Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma$
Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma
Published: March 1st 2001 | Updated:

N. L. Barlett

Articles by N. L. Barlett

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care